1. A: inhibition of the erbB2 receptor abolished the protective effects of NRG1 on cTnI and cTnT in NRVM. NRVM were treated with Dox-NRG1 (20 ng/ml) in the presence of AG879 (10 μM), AG1478 (10 μM), or the anti-erbB2 antibody (Ab; clone 9G6, 6 μg/ml).
A: inhibition of the erbB2 receptor abolished the protective effects of NRG1 on cTnI and cTnT in NRVM. NRVM were treated with Dox-NRG1 (20 ng/ml) in the presence of AG879 (10 μM), AG1478 (10 μM), or the anti-erbB2 antibody (Ab; clone 9G6, 6 μg/ml). Protein levels of cTnI and cTnT were determined 48 h after the Dox treatment by Western blot analysis. The Western blots are representative of at least 3 independent experiments. B: inhibitors of phosphatidylinositol 3-kinase, Akt, or mTOR abolished the protective effects of NRG1 on cTnI and cTnT in NRVM. NRVM were treated with Dox-NRG1 (20 ng/ml) in the presence of LY (LY; 10 μM), Akti-1/2 (Akti; 5 μM), or rapamycin (10 nM). Protein levels of cTnI and cTnT were determined 48 h after the Dox treatment by Western blot analysis. The Western blots are representative of at least 3 independent experiments.
Yun Bian et al. Am J Physiol Heart Circ Physiol 2009;297:H1974-H1983
©2009 by American Physiological Society